Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Comparative analysis of melphalan versus busulphan T-cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia.

Sellar RS, Mehra V, Fox TA, Grigg A, Kulasekararaj A, Sarma A, de Lavallade H, McLornan D, Raj K, Mufti GJ, Pagliuca A, Mackinnon S, Chakraverty R, Fielding AK, Carpenter B, Kottaridis PD, Khwaja A, Peggs KS, Thomson KJ, Morris EC, Potter VT.

Br J Haematol. 2019 Oct;187(1):e20-e24. doi: 10.1111/bjh.16136. Epub 2019 Aug 8. No abstract available.

PMID:
31396948
2.

Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation.

Patel K, Parmar S, Shah S, Shore T, Gergis U, Mayer S, van Besien K.

Biol Blood Marrow Transplant. 2016 Mar;22(3):456-61. doi: 10.1016/j.bbmt.2015.10.022. Epub 2015 Oct 31.

3.

Rapid recovery of lymphocyte subsets is not associated with protection from relapse of myelodysplastic syndromes and acute myeloid leukaemia after haematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab.

Matthews K, Lim Z, Pearce L, Pagliuca A, Alejandro Madrigal J, Mufti GJ, Barber LD.

Br J Haematol. 2010 Jun;149(6):879-89. doi: 10.1111/j.1365-2141.2010.08164.x. Epub 2010 Mar 21.

PMID:
20346011
4.
5.

Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.

Czajczynska A, Günther A, Repp R, Humpe A, Schub N, Raff T, Nickelsen M, Schrauder A, Schrappe M, Kneba M, Gramatzki M.

Biol Blood Marrow Transplant. 2013 Nov;19(11):1632-7. doi: 10.1016/j.bbmt.2013.07.003. Epub 2013 Jul 11.

6.

High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia.

Steckel NK, Groth C, Mikesch JH, Trenschel R, Ottinger H, Kordelas L, Mueller-Tidow C, Schliemann C, Reicherts C, Albring JC, Silling G, Schmidt E, Berdel WE, Lenz G, Ditschkowski M, Beelen DW, Stelljes M.

Br J Haematol. 2018 Mar;180(6):840-853. doi: 10.1111/bjh.15137. Epub 2018 Feb 21.

PMID:
29468631
7.

Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1.

Marsh RA, Bleesing JJ, Chandrakasan S, Jordan MB, Davies SM, Filipovich AH.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1641-5. doi: 10.1016/j.bbmt.2014.06.003. Epub 2014 Jun 9.

8.

Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma.

Ria R, Falzetti F, Ballanti S, Minelli O, Di Ianni M, Cimminiello M, Vacca A, Dammacco F, Martelli MF, Tabilio A.

Hematol J. 2004;5(2):118-22.

PMID:
15048061
9.

Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.

Davies JK, Hassan S, Sarker SJ, Besley C, Oakervee H, Smith M, Taussig D, Gribben JG, Cavenagh JD.

Br J Haematol. 2018 Feb;180(3):346-355. doi: 10.1111/bjh.14980. Epub 2017 Oct 26.

PMID:
29076145
10.

Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.

Saikia TK, Parikh PM, Tawde S, Amare-Kadam PS, Rajadhyaksha S, Chhaya S.

Natl Med J India. 2004 Mar-Apr;17(2):71-3.

PMID:
15141598
11.

Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant.

Nikolousis E, Robinson S, Nagra S, Brookes C, Kinsella F, Tauro S, Jeffries S, Griffiths M, Mahendra P, Cook M, Paneesha S, Lovell R, Kishore B, Chaganti S, Malladi R, Raghavan M, Moss P, Milligan D, Craddock C.

Leuk Res. 2013 May;37(5):561-5. doi: 10.1016/j.leukres.2013.01.010. Epub 2013 Feb 5.

PMID:
23395505
12.

Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.

Marsh RA, Rao MB, Gefen A, Bellman D, Mehta PA, Khandelwal P, Chandra S, Jodele S, Myers KC, Grimley M, Dandoy C, El-Bietar J, Kumar AR, Leemhuis T, Zhang K, Bleesing JJ, Jordan MB, Filipovich AH, Davies SM.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1460-70. doi: 10.1016/j.bbmt.2015.04.009. Epub 2015 Apr 10.

13.

Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT.

Ringdén O, Labopin M, Schmid C, Sadeghi B, Polge E, Tischer J, Ganser A, Michallet M, Kanz L, Schwerdtfeger R, Nagler A, Mohty M; Acute Leukaemia Working Party of the EBMT.

Br J Haematol. 2017 Feb;176(3):431-439. doi: 10.1111/bjh.14428. Epub 2016 Nov 23.

PMID:
27879990
14.

Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies.

Kanda J, Long GD, Gasparetto C, Horwitz ME, Sullivan KM, Chute JP, Morris A, Shafique M, Li Z, Chao NJ, Rizzieri DA.

Biol Blood Marrow Transplant. 2014 Feb;20(2):257-63. doi: 10.1016/j.bbmt.2013.11.010. Epub 2013 Nov 20.

15.
16.
18.

Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.

Slack JL, Dueck AC, Fauble VD, Sproat LO, Reeder CB, Noel P, Khera N, Betcher JA, Klein JL, Leis JF, Adams RH.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1167-74. doi: 10.1016/j.bbmt.2013.05.001. Epub 2013 May 7.

19.

High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single-centre experience.

Olavarria E, Kanfer E, Szydlo R, O'Brien S, Craddock C, Apperley J, Goldman J.

Br J Haematol. 2000 Mar;108(4):769-77.

PMID:
10792282
20.

Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.

van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L, Jones D, Del Cerro P, Bennett D, Casey B, Odenike O, Thirman M, Daugherty C, Wickrema A, Zimmerman T, Larson RA, Stock W.

J Clin Oncol. 2005 Aug 20;23(24):5728-38. Epub 2005 Jul 11.

PMID:
16009946

Supplemental Content

Support Center